( prescription consumer and animal heal...)Media Advisory: ACC Updated Schedule,Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Media Advisory: ACC Updated Schedule
prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
CONTACT: Media Contact, Lee A. Davies, +1-908-298-7127, or InvestorContact, Alex Kelly, +1-908-298-7436
Web site: http://www.schering-plough.com/
Company News On-Call: http://www.prnewswire.com/comp/777050.html /
Ticker Symbol: (:SGP)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>
Related medicine technology :
1. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
2. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
3. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
4. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
5. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
6. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
7. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
8. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
9. Boston Scientific Announces Schedule for EuroPcr 2007
Post Your Comments:
Breaking Medicine Technology:At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4Commercial Insurance Buyers Benefit From Ample Capacity 14306 1Commercial Insurance Buyers Benefit From Ample Capacity 14306 2Commercial Insurance Buyers Benefit From Ample Capacity 14306 3UAB professors book promises solution for teaching evolution without conflict 10199 1UAB professors book promises solution for teaching evolution without conflict 10199 2A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 1A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 2A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 3A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 4
[0] At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease[0] Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien[0] Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Other Medicine Technology:CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate 2CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate 3CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate 4TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 2TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 3
CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product CandidateTARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
Breaking Medicine News(10 mins):Health News:Talyst and MultiCare Partner to Improve Patient Safety 2Health News:Talyst and MultiCare Partner to Improve Patient Safety 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 4Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 5Health News:The Breema Center Presents a Yearlong Campaign to Transform Stress into Harmony in 2010 and Beyond 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 3Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2
[0] Talyst and MultiCare Partner to Improve Patient Safety[0] LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference[0] The Breema Center Presents a Yearlong Campaign to Transform Stress into Harmony in 2010 and Beyond[0] Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions[1] Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential
Other Medicine News:Health News:Work Absence Due to Headaches Has a Substantial Socio-economic Effect 2Health News:United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine 2Health News:EU Considers Allowing Cloned Meat, Milk on Market 2
Work Absence Due to Headaches Has a Substantial Socio-economic EffectSuccess of Hip Replacement Surgery Decided by GenesUnited States Department of Defense Selects Ichor Medical Systems to Develop Biodefense VaccineBlood Pressure is a Measure of Country’s HappinesEU Considers Allowing Cloned Meat, Milk on MarketChildren Infected With HIV at Birth Do Survive into Adolescence
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |